Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes||GAP T cells||Anti-GPC3-scFvGC33-CAR are autologous T-cells that have been engineered to express a chimeric antigen receptor (CAR) based on an antibody (GC33) that targets GPC3, which may induce lysis of GPC3-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02932956||Phase I||Cyclophosphamide + Fludarabine Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes||Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)||Active, not recruiting||USA||0|